The Latin America, Middle East and Africa Antimicrobial Resistance Diagnostics Market would witness market growth of 11.9% CAGR during the forecast period (2022-2028).
The development of new antimicrobials, better management of sick patients, and greater antimicrobial stewardship are all made possible by rapid and thorough diagnostics, which are essential for managing antimicrobial resistance. Certain illnesses, such as ventilator-associated pneumonia and sepsis, might increase mortality if proper antibiotic therapy is delayed. The early start of targeted narrow-spectrum therapies with proven antimicrobial activities against the infection's causative factor will be made possible by the rapid determination of pathogenic organisms and antimicrobial resistance, which will alter how clinicians manage infection.
Rapid diagnostics are ultimately aiming to identify the pathogen and its antimicrobial susceptibility using clinical samples at the point of care in less than 30 minutes. Presently, providing a thorough microbiological diagnosis prior to the second dosage of empirical treatment is considered to be adequate to enhance patient outcomes and stewardship.
The primary drivers of the market expansion are the high illness burden caused by pathogens including streptococcus pneumonia, C. difficile infections, MRSA, and others along with the sharp increase in the prevalence of infections caused by AMR. Additionally, increased regulatory approvals of medical diagnostics and the rising need for technologically sophisticated diagnostic tools to manage AMR are also projected to promote the growth of the market. Antimicrobial resistance's growing danger is anticipated to help the industry grow. Global governments are working to raise the standard of diagnostics for accurate point-of-care diagnosis.
In the UAE, the national action plan (NAP) on AMR was created to outline the current plans for national responses to AMR in the fields of food safety, environmental protection, and human and animal health. Technical subcommittees took the lead in developing and implementing strategies and activities in particular fields, like antimicrobial stewardship programs (ASP), surveillance, AMR prevention and control, and infection prevention and control (IPC). Together with other relevant ministries, authorities, organizations, research institutes, comparison laboratories, and other institutions, these activities will be carried out. As a consequence, AMR testing is gaining momentum in the region and is driving the growth of the antimicrobial resistance diagnostics market.
The Brazil market dominated the LAMEA Antimicrobial Resistance Diagnostics Market by Country in 2021; thereby, achieving a market value of $131.7 million by 2028. The Argentina market is showcasing a CAGR of 12.5% during (2022 - 2028). Additionally, The UAE market would register a CAGR of 11.6% during (2022 - 2028).
Based on Technology, the market is segmented into PCR, Immunoassay, NGS, Microbiology Culture, Mass Spectrometry, Rapid & Point of Care and Others. Based on End User, the market is segmented into Hospitals, Diagnostic Laboratories and Pharmaceutical, Biotechnology Companies & Others. Based on Pathogen, the market is segmented into Methicillin Resistant Staphylococcus Aureus (MRSA), Clostridium Difficile (CD), Drug Resistant Campylobacter (DRC), Drug Resistant Streptococcus Pneumoniae (DRSP), Drug Resistant Neisseria Gonorrhoeae (DRNG), Drug Resistant Salmonella (DRNTS) and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Global Antimicrobial Resistance Diagnostics Market is Predict to reach $5.7 Billion by 2028, at a CAGR of 6.1%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, BioMérieux S.A., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Danaher Corporation, Accelerate Diagnostics, Inc., Hologic, Inc., Visby Medical, Inc., Vela Diagnostics Pte. Ltd. (Luye Medical Group Co., Ltd) and Molsid S.A.S.
By Technology
By End User
By Pathogen
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
